EC clears Pharming’s Joenja for APDS in Europe
Bottom line
Pharming said the European Commission has granted marketing authorization for Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, or APDS, in adults and pediatric patients age 12 and older, making it the first approved treatment for the rare primary immunodeficiency in the European Union. The approval follows a positive CHMP opinion adopted on March 26, 2026, and applies across the EU, as well as Norway, Iceland, and Liechtenstein. Joenja is an oral PI3Kδ inhibitor, and Pharming has said the decision is based on clinical data showing reductions in lymphadenopathy and increases in naïve B cells in patients with APDS. (nasdaq.com)
Why it matters: While this is a human medicine approval rather than a veterinary one, it’s a notable example of how regulators are handling ultra-rare, genetically defined immune disorders and targeted therapies. For veterinary professionals, especially those following comparative immunology, translational medicine, or specialty referral trends, the decision underscores continued momentum behind precision treatments aimed at specific molecular pathways, rather than broad symptomatic management alone. It also highlights the growing regulatory acceptance of approvals in very small populations when biomarker and clinical data are aligned. (ema.europa.eu)
What to watch: Next will be country-level reimbursement, launch timing across Europe, and whether Pharming can expand access in younger children after mixed regulatory progress elsewhere, including a U.S. Complete Response Letter for ages 4 to 11 in February 2026. (live.euronext.com)
Key facts
- Drug
- Joenja (leniolisib)
- Indication
- Activated phosphoinositide 3-kinase delta syndrome (APDS)
- Population
- Adults and pediatric patients age 12 and older
- Approval
- European Commission marketing authorization
- Approval date
- May 22, 2026
- Region
- All 27 EU member states, plus Norway, Iceland, and Liechtenstein
- Mechanism
- Oral PI3Kδ inhibitor
- Trial finding
- Reduced lymphadenopathy and increased naïve B cells versus placebo over 12 weeks
- Regulatory context
- Positive CHMP opinion adopted March 26, 2026
Pharming has secured European Commission approval for Joenja (leniolisib), clearing the oral PI3Kδ inhibitor for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients age 12 and older. The May 22, 2026, decision gives the company its first full EU authorization for the drug and makes Joenja the first therapy specifically approved for APDS in Europe. The centralized authorization is valid in all 27 EU member states, plus Norway, Iceland, and Liechtenstein. (nasdaq.com)
The approval builds on a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, adopted on March 26, 2026. EMA described the filing as a marketing authorization under exceptional circumstances, a route often used when a disease is so rare that comprehensive data are difficult to obtain. That framing is important context for APDS, a very rare inborn error of immunity driven by hyperactivation of the PI3Kδ pathway. (ema.europa.eu)
Pharming and EMA both point to the same core efficacy story. In the pivotal randomized, placebo-controlled phase III trial, leniolisib met its co-primary endpoints over 12 weeks, significantly reducing lymphadenopathy and increasing the proportion of naïve B cells compared with placebo. Longer-term follow-up and related analyses have also suggested durable improvements in lymph node size, spleen volume, and immune cell markers, while the drug was generally reported as well tolerated in the studied population. (pmc.ncbi.nlm.nih.gov)
The European approval also fits into a broader global rollout. Joenja was already approved in the U.S. for patients 12 and older in March 2023, according to Pharming, and the company has since expanded into other markets. In March 2026, Japan approved leniolisib for patients age 4 and older, which Pharming described as the first approval anywhere for children ages 4 to 11. That contrasts with the U.S., where the FDA issued a Complete Response Letter on February 1, 2026, for the company’s supplemental application in that younger age group. (pharming.com)
Outside the EU process itself, the U.K. has already provided a signal on access. NICE recommended leniolisib in April 2025 for APDS in people age 12 and older, saying the cost-effectiveness estimates were within the range it considers an acceptable use of NHS resources. NICE had earlier called it the first licensed treatment for the ultra-rare immune disorder recommended for NHS use in England. That suggests that, beyond regulatory clearance, health-system willingness to fund the drug is becoming a key part of the commercialization story. (nice.org.uk)
Pharming’s public comments have emphasized the milestone nature of the decision, and trade coverage has echoed that framing, describing the approval as a first for the European APDS community. I didn’t find substantial independent expert reaction published immediately around the EC decision from major academic immunology groups, but the regulatory and reimbursement milestones themselves point to growing clinical acceptance of pathway-targeted treatment in this niche disorder. That’s an inference based on the CHMP recommendation, EC approval, NICE endorsement, and the supporting trial literature. (nasdaq.com)
Why it matters: For veterinary professionals, this is not a practice-changing animal health story, but it is relevant as a window into how precision immunology is advancing in rare disease. The Joenja decision shows regulators continuing to support targeted therapies for narrowly defined, genetically confirmed conditions, even when trial populations are necessarily small. For clinicians and industry watchers in veterinary medicine, that trend matters because comparative immunology, biomarker-led development, and orphan-style regulatory pathways increasingly shape expectations across both human and animal health innovation. (ema.europa.eu)
What to watch: The next phase is less about whether Joenja works and more about how broadly and quickly patients can access it. Watch for European launch sequencing, national reimbursement decisions, publication of the final EU product label materials, and any renewed regulatory movement in younger pediatric populations, especially in the U.S. and Europe. Pharming has also said it expected launches in Japan and Europe in 2026, so commercial execution will be the next test. (live.euronext.com)